AU Patent

AU2024343419A1 — Sparsentan for treating immunoglobulin a nephropathy (igan)

Assigned to Travere Therapeutics Inc · Expires 2026-04-09 · 0y expired

What this patent protects

Methods of treating immunoglobulin A nephropathy are provided, including methods comprising administering a compound having structure (I), also named Sparsentan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

USPTO Abstract

Methods of treating immunoglobulin A nephropathy are provided, including methods comprising administering a compound having structure (I), also named Sparsentan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024343419A1
Jurisdiction
AU
Classification
—
Expires
2026-04-09
Drug substance claim
No
Drug product claim
No
Assignee
Travere Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.